Abatacept biosimilar - Hanwha Biologics

Drug Profile

Abatacept biosimilar - Hanwha Biologics

Latest Information Update: 11 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanwha Biologics
  • Class Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunoconjugates; Immunoglobulin fusion proteins
  • Mechanism of Action CD80 antigen inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Arthritis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Feb 2015 Discontinued - Clinical-Phase-Unknown for Arthritis in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top